The B7-1 molecule, expressed on antigen presenting cells (APC), provides a crucial costimulatory signal for T cell activation. Recent studies demonstrate the existence of alternative, non-B7-1 CTLA4 counter-receptors in mice and humans. Here, we describe the molecular cloning and demonstrate costimulatory function of the murine B7-2 (mB7-2) gene. Murine B7-2 cDNA encodes a member of the Ig supergene family that binds CTLA4-Ig and stains with the GL1 but not anti-mB7-1 mAb. Murine B7-2 costimulates the proliferation and interleukin 2 production of CD4+ T cells and this costimulation can be inhibited by either CTLA4-Ig or GL1 mAb. Identification of the B7-2 molecule will permit further manipulation of the B7:CD28/CTLA4 costimulatory pathway which has been shown to be involved in the prevention of tolerance, induction of tumor immunity, and most recently, in the pathogenesis of autoimmunity.
Materials and Methods
Isolation ofmB7-2cDNA. A cDNA library was prepared in the pCDM8 expression vector using poly(A)' RNA from cyclic AMP (300 /~g/ml)-stimulated M12 murine B cell line (RNA harvested at 0, 8, 19, 27, 32 , and 48 h) (16) . COS cells were transfected with the activated M12 cDNA library DNA by DEAE-dextran transfection (17) . Cells were harvested after 47 b, incubated with 10 P,g/ml bCTLA4-Ig and mCD28-Ig, and binding cells were isolated by panning on goat anti-human IgG coated plates (18) . Episomal DNA was isolated, transformed into Escherichia coli DH10B/P3, and the plasmid DNA reintroduced into COS cells via spheroplast fusion. Transfected cells were harvested after 47 h. Cells expressing B7-1 were removed by incubation with anti-mB7-1 mAb (16-10A1) and immunomagnetic bead depletion using antimouse IgM and IgG coated beads. Transfectants were selected by panning with hCTLA4-Ig and mCD28-Ig as described above, and plasmid DNA was transformed into E. coli . A third round of selection, identical to the second round was performed, after which plasmid DNA was isolated from individual transformants. Six of seven isolated plasmids contained a 1.2-kb cDNA insert . COS cells transfected with these plasmids bound CTLA4-Ig but not control Ig fusion protein.
DNA Sequence Analysis. Murine B7-2 cDNA insert (clone 4) was subcloned into the pKSII-plasmid. The cDNA insert was sequenced on both strands using synthetic oligonucleotide primers and dye-labeled terminator/Taq polymerase chemistry, and analyzed on an automated fluorescent DNA sequencer (Applied Biosystems, Foster City, CA). These sequence data are available from EMBL/ GenBank/DDBJ under accession number L25606 .
B7 Hybridization Probes and RNA Blot Hybridization. The entire mB7-2 cDNA was used as a probe for RNA hybridizations. RNA was prepared from the unstimulated and c-AMP-stimulated M12 B cell line (16) and from the B cell lymphomas, A20 and TA3, the NS-1 plasmacytoma, and 70 Z pre-B cell lines. RNA preparation, detailed characterizations, and sources of these cells are as described (19) . RNA was denatured with formaldehyde, electrophoresed on an agarose gel, and blotted onto nitrocellulose membranes (Schleicher & Schuell, Inc., Keene, NH). The mB7-2 and actin cDNA insert (control for RNA amount and integrity) were labeled by random oligonucleotide priming using tx 31 P-labeled dCTP and dATP and the Klenow Fragment of DNA polymerase. Hybridization, washing, and autoradiography were performed as described previously (11) .
COS Cell Transfection . Transient expression of cDNA clones in COS cells was performed as described previously (17) . COS cells were transfected with cDNAs encoding mB7-1 (5), B7-2 or hB7-2, or with pCDNAI vector alone. Transfected COS cells were used 72 h after the addition of DNA.
Fluorescence Activated Cell Sorting. Purified murine B cells were stimulated in vitro with LPS (10 Ecg/ml) and dextran sulfate (20 Ag/ml) (6) , and stained with anti-B7 (16-10A1) (6), GLI mAb (14), hCTLA4-Ig (2), or isotype-matched controls, followed by goat anti-hamster Ig FITC, goat anti-rat Ig FITC, or donkey anti-human Ig FITC, respectively. The GL1 mAb identifies a 65-100 kD glycoprotein expressed at low levels on resting murine B cells and expression increases with activation . GLI mAb blocks the binding of CTLA4-Ig on LPS-activated B blasts and, in vivo, functionally blocks the induction of IgM Ab formation to BSA-FITC. Cells were then washed, fixed in 1% paraformaldehyde in PBS, and analyzed by flow cytometric analysis.
Proliferation Assay. Mouse T cells were purified as described previously (20) . Briefly, spleen cells were depleted of erythrocytes by treatment with Tris/NH4C1 . T cells were enriched by nylon wool mB7-2 Costimulates T Cell Proliferation and 11,2 Production fractionation . CD4' T cells from BALB/c mice were purified by treatment with a mixture of anti-MHC class II and anti-CD8 mAbs and rabbit complement (Cedarlane Laboratories, Hornby, ON, Canada). Murine T cells were stimulated with either soluble anti-CD3 (1 :100-1 :3,000 dilution of tissue culture supernatant) or PMA (Calbiochem-Novabiochem Corp ., La Jolla, CA) at 1-20 ng/ml. Human CD28' T lymphocytes were purified as described previously (21) and stimulated with PMA at 1 ng/ml final concentration. COS cell transfectants were incubated with 25 t~g/ml of mitomycin C for 3 h, washed extensively, and then added at a concentration of 2 x 104 cells/well. The specificity of the stimulation with COS-transfected cells was assayed by the addition of antim137-1 mAb (16-10M) (6), GL1 mAb (14), or CTLA4-Ig (2), and appropriate isotype-matched control Abs. The cells were pulsed with 1 ACi of [3H]thymidine (ICN Flow, Costa Mesa, CA) during the last 16 h of a 60-h culture, harvested onto filters, and counted. Microcultures were set up in triplicate in 96-well plates as described. T cells, (10s/well), were cocultured with transfectants in 0.2 ml of RPMI supplemented with 10% FCS, 4 MM L-glutamine, 10 mM Hepes, and antibiotics.
11,2 Assay. ILr2 accumulation was assayed using an 11,2 ELISA kit (Endogen, Inc., Boston, MA) according to the manufacturer's instructions . Supernatants for analysis were removed from microculture wells after 24 h of culture. Supernatants from triplicate cultures were pooled and assayed in duplicate by ELISA.
Results
Murine B7-2 cDNA, Isolation and Expression . A 1.2-kb cDNA encoding a CTLA4 binding protein was isolated by cDNA expression cloning from a cDNA library prepared from cyclic AMP-activated M12 murine B lymphoma cells. When transfected into COS cells, this cDNA directed the synthesis of a molecule which bound CTLA4-Ig (Fig. 1) . Furthermore, the mB7-2 COS transfectants stained with the GL1 mAb which identifies a non-mB7-1, CTLA-4 counter-receptor expressed on activated murine B cells. This mAb is a potent inhibitor of costimulation delivered by murine APCs (14) . A very slight shift in fluorescence intensity was observed when anti-mB7-1 mAb was used to stain mB7-2 transfected COS cells. In contrast, mB7-1 COS transfectants bound CTLA4-Ig and stained with anti-mB7 but not GL1 mAb. None of these transfected COS cells bound control Ig fusion protein or isotype-matched control mAbs . Similarly, COS cells transfected with vector alone did not bind any of the aforementioned reagents ( Fig. 1 and data not shown) .
The mB7-2 cDNA is comprised of 1,183 nucleotides, and exhibits a single large open reading frame of 927 nucleotides . The encoded polypeptide is 309 amino acids long and exhibits many features common to type I Ig superfamily membrane proteins (Fig. 2 A) . The NHZ terminus of the B7-2 protein (amino acids 1-23) has the characteristics of a secretory signal peptide with a predicted cleavage after the alanine at position 23 . potential Winked glycosylation sites . The glycoprotein immunoprecipitated by the GM mAb has a molecular weight of 60-100 kd, which reduces to 34 kD after N-glycanase treatment (14), suggesting that the mB7-2 protein is heavily glycosylated. Comparison ofboth nucleotide and amino acid sequences ofmB7-2 with the GenBank and EMBL databases and with our recently identified human B7-2 has shown that only the human B7-2 protein is closely related, with 50% amino acid identity, and that murine and human B7-1 are distantly related. The alignment of murine and human B7-1 and B7-2 protein sequences shows that the homology is concentrated in the Ig-like domains with the transmembrane, and cytoplasmic domains being much less conserved (Fig. 2  B) . Comparison of the four characterized B7 proteins (Fig.  2 B) reveals that the IgV-and Ig-C-like domains demonstrate 14 and 18% amino acid identity, respectively. In general, conserved amino acids other than those involved in the canonical Ig structure tend to be concentrated in the sequences at the bottom of the IgV and the top of the IgC domains . In particular, the sequence SQD(P/N)(E/V)(S/T)EL(Y/F), predicted to be the loop between the D and E (3 strands of the IgC domain, is conserved (22) . Whether this sequence is required for the structural integrity of B7-like molecules or represents a required motif for CTLA4 binding is not yet clear. But since human B7-1, human B7-2, murine B7-1, and murine B7-2 all bind to human CTLA4, the homologous amino acids probably represent those necessary to comprise a CTLA4 binding sequence . Expression ofmB7-2 mRNA. Two mRNA transcripts of 1.8 and 3.1 kb were identified by hybridization to the mB7-2 cDNA (Fig. 3) . RNA blot analysis of c-AMP-treated M12 cells demonstrates that B7-2 is not expressed in unstimulated M12 cells, but is induced by c-AMP treatment by 8 h and declines only slightly by 27-48 h. In contrast, mB7-1 expression induced by c-AMP is highest after 27 h (23) . mB7-2 mRNA expression was detected in the TA3 B cell line, a frequently used murine APC line. Very low levels of mB7-2 mRNA were seen in the A20 B cell line but are sufficient for moderate levels of mB7-2 cell surface expression as shown by GL1 staining of A20 cells (data not shown) . However, mB7-2 mRNA was not detected in the NS-1 plasmacytoma or the pre-B cell line 70Z. In contrast, B7-1 mRNA is expressed in NS-1 and A20 cells but not 70Z or TA3 (5) .
Induction of mB7-2 on LPS/Dextran Stimulated Murine B Cells. Murine B cells from wild-type and B7-1-deficient mice were isolated and activated with LPS/dextran for 72 h. As seen in Fig. 4 , upon stimulation both B7-1 wild-type and deficient B cells bind CTLA4-1g. When GL1 mAb was used to stain B7-1 wild-type and B7-1-deficient B cells, a similar pattern of staining was observed . However, low levels of GL1 staining were seen on unstimulated B cells. In contrast, antimB7-1 mAb stained LPS/dextran-stimulated wild-type B cells but not B cells isolated from mB7-1-deficient mice. These results are consistent with those recently observed by Freeman et al. (12) .
Costimulatory Activity of mB7-2 . To determine whether mB7-2 can costimulate submitogenically activated murine T cells, CD4+ murine T cells were isolated and activated with either PMA or soluble anti-CD3 mAb (145-2C11) . As shown in Fig. 5 A, PMA-activated T cells were costimulated by both mB7-1 and mB7-2 but not vector-transfected COS cells . Similarly, anti-CD3-activated T cells demonstrated significant proliferation when cocultured with either mB7-1 or mB7-2 COS transfectants but not vector transfectants . (Fig. 5 B) . Both proliferation and IL-2 accumulation induced by mB7-2 costimulation were inhibited by CTLA4-Ig and by the GM mAb (Fig. 6 ) . This result is consistent with the recently demonstrated inhibitory effect of GM on costimulatory responses induced by heterologous APCs (14). While mB7-1 mAb stained mB7-2 cDNA transfected COS cells only very weakly, mB7-1 mAb consistently inhibited proliferation and IL-2 accumulation induced by mB7-2 by ti 30-50% (five experiments), suggesting the existence of a weakly crossreactive epitope . In contrast, mB7-1 costimulatory activity was blocked CTLA4-Ig and by the anti-mB7-1 mAb but not by GM mAb.
Both human B7-1 and murine B7-1 transfected COS cells have been previously shown to provide costimulation to both human and murine T cells (5) . We, therefore, also examined the capacity of human and murine B7-2 transfected COS to 
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Freeman et al . Figure 6 . Inhibition of mB7-1 and mB7-2 costimulation. Microcultures were set up as described with 105 BALB/c T lymphocytes . All T cell populations were depleted of detectable accessory cells, as demonstrated by a lack of an anti-CD3 (1 Ag/ml) or PMA (5 ng/ml) response in the absence of a source of costimulatory activity. Wells contained 2 x 104 mitomycin C-treated COS cells transfected with vector alone, mB7-1, or mB7-2 . Ab reagents were added at a final concentration of. CTLA4-Ig and control Ig fusion protein, 2 ug/ml ; GLl mAb and rat control mAb, 0 .1 14g/ml ; and anti-B7-1 mAb and hamster control mAb, 1 1&g/ml. Supernatants were harvested at 24 h for IL2 ELISA assay. Cultures were costimulate across species . Fig. 7 B demonstrates that submitogenically activated murine T cells proliferate in response to hB7-2 COS transfectants, as well as to mB7-1 and mB7-2 COS transfects . Similarly, human PMA-activated T cells proliferate in response to mB7-2, as well as to hB7-2. (Fig.  7 A) .
Discussion
In this report, we describe the molecular cloning, expression, and costimulatory function ofthe mB7-2 gene. Although demonstrating only 25% amino acid identity with mB7-1, mB7-2 cDNA encodes a member of the Ig supergene family that binds CLTA4-Ig and costimulates T cells to produce IL-2 and proliferate . In contrast to mB7-1, mB7-2 transfected COS cells stain with the GLI mAb but do not stain with mB7-1 mAb . Costimulation induced by mB7-2 transfectants is inhibited by CTLA4-Ig and GL1 mAb. These results demonstrate that the mB7-2 cDNA encodes a second CTLA4 counter-receptor that is identified by the GL1 mAb and which costimulates T cell proliferation and IL-2 production .
The cloning of mB7-2 and its reactivity with the GL1 mAb confirms the existence of a novel murine CTLA4 counterreceptor expressed within hours after B cell activation. These data are consistent with recent experiments suggesting the existence of additional ligands for CTLA4, distinct from mB7-1, on activated splenic B cells (12, 13, 24) . In this manuscript, we show that LPS/dextran-activated murine B cells derived from the mB7-1-deficient mouse strain bind CTLA4-Ig and stain with the GL1 but not with anti-mB7-1 mAb. Recently, Lenschow et al. (13) demonstrated that by 6 h after activation, murine B cells express a CTLA4 counter-receptor distinct from mB7-1 . This molecule appears on the cell surface -24 h earlier than mB7-1 and unlike mB7-1, its expression is induced by Con A. GL1 is expressed at low levels on unstimulated murine B cells and rapidly increases with activation . The GL1 mAb abrogates costimulation induced by populations containing activated murine B cells (14). Cyclic AMP induces mB7-2 mRNA more rapidly than mB7-1 mRNA, suggesting that mB7-2, like mB7-1, is upregulated by cross-linking ofMHC class II (23) but is expressed sooner than mB7-1. Taken together, these results suggest that the mB7-2 molecule appears earlier than mB7-1 and is responsible, at least in part, for the costimulation delivered by APCs within the first 24 h.
Many experiments examining the costimulatory capacity of natural APCs use chemically fixed APCs (1, 30) . We have found that costimulatorys have very different sensitivities to fixation. The costimulatory capacity ofB7-2 is partially sensitive to paraformaldehyde fixation, whereas B7-1 costimulation is insensitive to paraformaldehyde fixation (5, Freeman, G., unpublished results) . ICAM-1 costimulation (27) is eliminated by paraformaldehyde fixation . Thus the costimulatory capacity ofnative APCs may be different than those ofchemically fixed APCs and should be considered when interpreting experiments using fixed APCs.
Virtually identical evidence exists for an early, non-B7-1, 2190 mB7-2 Costimulates T Cell Proliferation and 11,2 Production CTLA4 counter-receptor in humans (hB7-2) (15, 25) . Between 12 and 24 h after activation, human B cells express a non-hB7-1, CTLA4 counter-receptor which costimulates CD28+ T cells to proliferate and secrete IL-2. This costimulation is abrogated by blocking with CTLA4-Ig and anti-CD28 Fab but not by anti-hB7-1 mAb (133) (15) . Recently, we have molecularly cloned the human B7-2 cDNA (25) . The hB7-2 cDNA demonstrates 26% amino acid identity with hB7-1 and 50% identity with mB7-2. Like hB7-1, hB7-2 costimulates T cell proliferation and IL-2 secretion and this costimulation is inhibited by both CTLA4-Ig and anti-CD28 Fab (25) . Whereas hB7-1 mRNA is not detected in unstimulated B cells, hB7-2 mRNA is constitutively expressed in unstimulated B cells and increases after activation. Since no CTLA4 counter-receptors are expressed on the surface of unstimulated B cells (15), the constitutive expression of hB7-2 mRNA suggests a posttranscriptional regulation of hB7-2 expression. Although mAbs directed against hB7 2 are currently unavailable, the constitutive expression of hB7-2 mRNA and the observed costimulatory capacity of 24-h activated human B cells suggests that hB7-2 also appears early after B cell activation. Whereas the signaling function of CTLA4 in murine and human systems has yet to be resolved, hB7-1 and hB7-2 appear to signal via CD28 (15, 25). Although we do not yet have an antimurine CD28 Fab to address this issue directly, we postulate that mB7-2 also signals via CD28. Indirect evidence for this hypothesis is derived from the observation that mB7-2 and hB7-2, like mB7-1 and hB7-1, costimulate T cell proliferation and IL-2 production across species barriers . These results demonstrate the striking evolutionary conservation displayed by murine and human B7-1 and B7-2 for their receptors CD28 and CTLA4 expressed on T lymphocytes.
These results indicate that the B7:CD28/CTLA4 pathway has additional levels of complexity. The biologic function(s) for multiple, sequentially induced CTLA4 counter-receptors remains to be elucidated . Howevef, the early appearance of B7-2 provides one mechanism for B cell-induced costimulation at a time before the induction of B7-1. Therefore, the early expression of B7-2 suggests that it may provide a critical costimulatory signal involved in the decision between immunity and anergy that is made by T cells within 24 h after activation (2, 26, 27 ) . Furthermore, it may be that B7-1 serves to amplify rather than initiate an immune response.
Recent data in the human system demonstrating a third CTLA4 counter-receptor suggest that the B7:CD28/CTLA4 pathway is even more complex. Specifically, B7-1-negative, activated human B cells express a BB1 molecule which is distinct from hB7-1 and hB7-2 (15). It may be that subpopulations of APCs differentially express these CTLA4 counterreceptors. It is presently unknown whether additional T cell receptors for the B7 family ofcostimulatory molecules exist. The capacity of the CD28-deficient mouse to generate an immune response and produce low levels of IL-2 is consistent with this hypothesis (28) . Since this pathway appears to be central to the initiation and amplification of a T cellmediated immune response, it is not surprising that it is highly regulated. Elucidating these levels of regulation should enable us to manipulate this critical costimulatory pathway which already has been shown to be involved in the regulation of tolerance (2, 29, 30) , induction of tumor immunity (31, 32, 
